TidalSense's £14.2m Financing Put 71% First In Line

TidalSense's visible £10.31 million of new equity has already reordered its capital structure. Four cash allotments created 5,102,992 B Ordinary shares at £2.02 each. That class now represents 70.86% of all issued shares, votes alongside the company's two other classes and is paid first among shareholders in the filed liquidation and return-of-capital waterfall.

The respiratory-diagnostics company announced a $19 million financing on 24 July, equivalent to the £14.2 million reported in sterling deal coverage. The public story is European commercialisation and preparation for the United States after regulatory approval and adoption by parts of the National Health Service.

The register reveals the bargain underneath that expansion. The visible B Ordinary cash represents 72.6% of the £14.2 million headline and leaves £3.89 million not yet mapped to that equity class. This does not make the announcement wrong. The balance could be unfiled equity, another financing instrument or a closing not yet visible in the public record.

It does establish a material class-level shift. The new class is dominant in the issued capital and protected first on the way down. The filings do not show how that class is divided among Cross-Border Impact Ventures, BGF, Airstream Capital and Foresight Group, so they do not establish control by any named investor.

Four Cash Allotments Created £10.31 Million Of B Shares

Independent reporting by MobiHealthNews identifies Cross-Border Impact Ventures as a new investor and BGF, Airstream Capital and Foresight Group as returning investors. It says the financing takes total funding to $40 million, including $11 million of grants.

The public announcement arrived in July, but the visible B Ordinary issuance is a sequence rather than a single-day transaction. The first and largest cash allotment occurred in December 2025. Three further issues followed in April, June and July.

The sequence shows that much of the capital was legally issued before the financing was publicly announced. It does not show that all four issues formed one contractual closing or that every announced investor participated on the same date.

That distinction matters for anyone trying to reconstruct runway. A July announcement does not mean the full amount arrived in July. More than £7.5 million of the visible B cash dates to December 2025, while another £2.78 million was issued from April through July.

The New Class Is 70.86% Of Issued Shares

The final July statement of capital records three classes and 7,201,037 shares in total.

B Ordinary holders can attend, speak and vote at general meetings and participate in written resolutions. The three classes vote together as if they were one class, with votes tied to shareholdings.

That makes the shift politically relevant as well as economic. A class containing more than seven in every ten issued shares carries most of the company's voting capital. But a class is not a shareholder. Without the allocation among investors, voting agreements and any contractual consent rights, the filing cannot identify who can assemble a majority or block a decision.

The distinction is especially important because BGF Investment Management remains registered as a person with significant control. That public status does not allocate the new B shares or support assigning the entire class to BGF.

The Company Entered The Sequence From Net Liabilities

TidalSense's accounts to 31 December 2024 predate every B Ordinary allotment. They are therefore a starting point, not a current cash statement.

The company moved from £1.93 million of net assets to £230,567 of net liabilities in one year. Its annual loss increased by 86%, while cash fell by 39%.

Those figures do not show that TidalSense was insolvent when the financing was announced. The balance-sheet date was more than eighteen months earlier, and the subsequent equity issues materially changed the company's resources. They do show the financial risk new money was being asked to absorb before large-scale commercialisation.

For private-market readers, that starting point helps explain why percentage ownership alone is an incomplete account of the deal. Capital entering a loss-making regulated medical-device company can negotiate both voting participation and priority if the company later distributes value in a lower-return outcome.

The Waterfall Protects B Capital First

The filed rights create four shareholder layers on a liquidation or return of capital. Company liabilities come before any shareholder distribution. Within the shareholder stack, the B Ordinary issue price is addressed first.

The token cross-class allocations in the filed formula do not change the commercial sequence. In plain language, B gets its issue price first, A follows, Ordinary receives a protected £6.5 million band after those two layers, and only then does the residual become proportional.

This is more balanced than a simple preference in which the old Ordinary class receives no distinct protection. B capital is first in line among shareholders, but the £6.5 million Ordinary layer preserves a later claim for the older class before the final pro-rata split.

The importance depends on the value available after liabilities. In a high-value outcome, every class can move through its protected layer and share the residual. In a lower-value outcome, the sequence determines which investors recover cash and which layers may not be reached.

TidalSense's structure therefore differs from Moa Technology's two-times Series C preference. Moa's new class represented 46.4% of issued shares and had an approximate two-times first layer. TidalSense's B class is much larger at 70.9%, but the first layer is based on issue price and is followed by separate protection for A and Ordinary capital.

The Financing Has A Commercial Case

TidalSense is not financing only a balance-sheet repair. Its product is designed to diagnose chronic obstructive pulmonary disease without conventional spirometry. Patients breathe normally into a handheld device for 75 seconds, producing a carbon-dioxide waveform that the company's models analyse.

BGF says N-Tidal Diagnose received a European Class IIa medical-device mark in March 2025 and launched into the National Health Service in September. It reports use in England, Wales and Scotland, while the company says the test can be administered by a healthcare professional without specialist qualifications.

That progress creates a fair case for the financing and its protections. Commercialising a regulated diagnostic requires clinical evidence, manufacturing, market access, sales capacity and continuing product development. Entering the United States adds another regulatory and commercial programme before the new market can contribute revenue.

The announced capital is intended to accelerate commercialisation in the UK, Ireland and Europe, prepare for US entry and extend the platform to other respiratory conditions, including asthma. Investors are taking execution and regulatory risk that the 2024 balance sheet could not absorb indefinitely.

This is the same broad private-market question visible in Humanoid's founder-financed recapitalisation and PaperShell's grant-backed factory funding gap: what protection does new capital receive for taking risk that older financing can no longer carry alone?

The Remaining £3.89 Million Is A Document Question

The £10,308,043.84 of visible B cash falls £3,891,956.16 below the £14.2 million headline. The gap is large enough to matter, but the public record does not yet explain it.

Several outcomes remain possible. A later return of allotment could add equity. Part of the financing could use another instrument. A closing may have occurred but not yet appeared in the filing history. The sterling amount could also reflect a broader transaction perimeter than the four visible B issues.

None of those possibilities can be selected from the current evidence. The safest conclusion is also the most useful one: 72.6% of the headline is visible in a clearly priced equity class, while 27.4% remains unmapped.

The next return of allotment should show whether more B shares enter at £2.02 or another class appears. The next confirmation statement may identify the owners of the dominant class. Updated articles or financing documents could reveal board, consent or governance rights that the capital statements do not capture.

The next accounts carry a different test. They should show how much cash remained after the financing sequence, how quickly commercialisation consumed it and whether product adoption began to change the operating trajectory.

TidalSense has raised capital to turn regulatory and early health-service progress into a larger commercial business. The filed price of that transition is already visible: £10.31 million of equity, 70.86% of issued shares and the first shareholder recovery layer for the B class.

The unresolved £3.89 million may change the denominator or the instrument mix. It does not change the central financing question. TidalSense now has to create enough commercial value to move through the protected shareholder layers and make the final pro-rata economics matter.